One in five people will develop skin cancer at some point in their lives, with more than three million cases in over two million people diagnosed annually in the U.S. Most patients are diagnosed with non-melanoma skin cancer (NMSC). Basal cell carcinoma is the most common type of NMSC, while squamous cell carcinoma is the second most common form. The majority of lesions are located on sun-exposed areas like the face, back of hands and neck. According to the NCCN guidelines, radiation therapy is a primary treatment option for NMSC, or a secondary option in case of positive margins post-surgery. Sensus Electronic Brachytherapy (eBx®) System® SRT-100 Visiontm provides a non-surgical treatment option for non-melanoma skin cancer. Unlike alternative brachytherapy procedures, which use radioactive isotopes, the Sensus System utilizes an isotope-free miniature X-ray source. The X-ray source delivers high dose radiation to the target area. Sensus eBx® can be delivered in a minimally shielded environment allowing the physician to remain in the room throughout treatment. During Sensus eBx®, a small, lightweight surface applicator is placed directly on the target lesion where the radiation is to be delivered. UDC is the first to offer this treatment in Indiana.

Surgical excision is the most common skin cancer treatment, but in certain patients, primary or postoperative radiotherapy can be an ideal alternative, with good to excellent cosmetic results. Sensus eBx® provides an additional treatment option for skin cancer with a variety of benefits including:

• targeted treatment resulting in good to excellent cosmesis.

• painless treatment using a small, lightweight applicator

• isotope-free radiation source requires minimal shielding

• fewer visits compared to external beam therapy

• better monitoring with presence of therapist

For more information you may visit their website at www.sensushealthcare.com

Here are some examples of patients after treatment.